# Nutrition Impact on Immunotherapy of Cancer

> **NCT06500234** · PHASE3 · RECRUITING · sponsor: **Qingdao Central Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Nutrition Disorders
- Immunotherapy
- Cancer
- Survival, Prosthesis

## Interventions

- **DRUG:** Megestrol Acetate and olanzapine
- **DRUG:** Starch powder 50 mg

## Key facts

- **NCT ID:** NCT06500234
- **Lead sponsor:** Qingdao Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500234, "Nutrition Impact on Immunotherapy of Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06500234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*